Targeting TDP-43 to treat Alzheimer's disease and related disorders
Official title: Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders
Funded at Fox Chase Chemical Diversity Center, INC · NIH-10893509 · Data updated 2026-11-12
This study is looking at a protein called TDP-43 to see how it affects memory loss in Alzheimer's and similar conditions, and it's testing new medicines that might help keep this protein from clumping together, which could lead to better treatments for people with these diseases.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fox Chase Chemical Diversity Center, INC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,363,709 |
| NIH project number | 5U01AG068823-04 |
| Project ID | NIH-10893509 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with Alzheimer's disease or related dementias, particularly those showing signs of TDP-43 involvement.
✕Less likely to help
Patients with other forms of dementia not associated with TDP-43 pathology may not benefit from this research.
What this research studies
This research investigates the role of TDP-43 protein in Alzheimer's disease and related dementias, focusing on how TDP-43 inclusions correlate with cognitive decline. The team is exploring small molecules that can inhibit the aggregation of TDP-43, potentially leading to new therapeutic options. By understanding the mechanisms of TDP-43 in Alzheimer's, the research aims to develop targeted treatments that could improve cognitive function in affected individuals. Patients may be involved in trials assessing the safety and efficacy of these new therapies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and quality of life for patients with Alzheimer's disease.
How similar studies have gone: While targeting TDP-43 is a relatively novel approach, preliminary studies suggest that similar strategies may have shown promise in treating related neurodegenerative conditions.
Where this research is happening
-
Fox Chase Chemical Diversity Center, INC
Doylestown, United States Active
Researchers
- Principal investigator: Reitz, Allen Bernard — Fox Chase Chemical Diversity Center, INC
- Study coordinator: Reitz, Allen Bernard
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.